Kovitz Investment Group Partners LLC Buys 18,128 Shares of Bristol Myers Squibb Company $BMY

Kovitz Investment Group Partners LLC grew its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 2.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 795,782 shares of the biopharmaceutical company’s stock after acquiring an additional 18,128 shares during the period. Kovitz Investment Group Partners LLC’s holdings in Bristol Myers Squibb were worth $35,890,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC increased its stake in shares of Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after buying an additional 4,935 shares during the period. Sivia Capital Partners LLC increased its position in Bristol Myers Squibb by 59.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 2,786 shares during the period. United Bank raised its holdings in shares of Bristol Myers Squibb by 15.0% in the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after purchasing an additional 3,277 shares in the last quarter. AlTi Global Inc. lifted its position in shares of Bristol Myers Squibb by 12.2% in the 2nd quarter. AlTi Global Inc. now owns 4,420 shares of the biopharmaceutical company’s stock worth $205,000 after purchasing an additional 482 shares during the period. Finally, AlphaQuest LLC boosted its stake in shares of Bristol Myers Squibb by 310.1% during the second quarter. AlphaQuest LLC now owns 18,944 shares of the biopharmaceutical company’s stock valued at $877,000 after purchasing an additional 14,325 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on BMY. The Goldman Sachs Group restated a “neutral” rating and set a $57.00 target price (up previously from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. UBS Group upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $46.00 to $65.00 in a research note on Wednesday, January 7th. Scotiabank reiterated a “sector perform” rating and issued a $60.00 target price (up previously from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Piper Sandler reissued an “overweight” rating and set a $66.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a research report on Wednesday, January 28th. Finally, Truist Financial set a $65.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, December 3rd. Nine analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and an average price target of $60.19.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Barclays initiated U.S. large‑cap biopharma coverage and included Bristol‑Myers Squibb among four preferred picks, arguing the sector could regain investor attention and highlighting BMY as a top choice. This institutional endorsement likely helped buying interest. Barclays launches U.S. biopharma coverage with four preferred picks
• Positive Sentiment: BMY reported completion of a mavacamten safety‑extension study update, which clarifies the long‑term safety profile for its hypertrophic cardiomyopathy program — a de‑risking event for a later‑stage asset and a potential long‑term revenue driver. BMY’s Mavacamten Safety Extension Wraps Up
• Positive Sentiment: Analyst/commentary pieces highlight BMY’s oncology franchise and new drug launches, noting cost cuts and a stronger 2026 outlook versus peers — reinforcing confidence in revenue stability and medium‑term growth. Bristol‑Myers Squibb: Oncology Franchise Remains A Core Strength
• Neutral Sentiment: Comparative analyst coverage (Zacks/Money pieces) argues BMY edges Merck in the 2026 setup due to product launches and cost actions — a relative positive versus peers but not new company‑specific catalysts. Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
• Neutral Sentiment: Coverage discussing an Iberdomide regulatory review and an AI partnership adds new angles to BMY’s mid‑cycle outlook; informative for pipeline expectations but not an immediate earnings swing. Iberdomide Review And AI Alliance Add New Angles To BMY Outlook
• Negative Sentiment: Zacks Research issued a series of downward revisions to several near‑term EPS estimates (notably Q1/Q2 2026 and FY2027 trims), which introduces caution around short‑term earnings momentum and could cap upside until upcoming results confirm guidance.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $60.66 on Monday. The business has a fifty day moving average of $56.22 and a 200 day moving average of $50.03. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The firm has a market capitalization of $123.53 billion, a price-to-earnings ratio of 17.58, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same quarter in the previous year, the firm posted $1.67 EPS. The firm’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, research analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.